Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imperial College Innovations Ltd.

This article was originally published in Start Up

Executive Summary

For Sir Richard Sykes, chairman of GlaxoSmithKline PLC and Rector of Imperial College of Science Technology & Medicine since the beginning of 2001, strong interaction between different faculties is the key to effectively exploiting the College's intellectual assets. The interdisciplinary approach taken by the College itself-its new BioMedical building built in the heart of the campus, close to Chemistry and Engineering-and by Imperial College Innovations Ltd., the College's technology transfer company, reflects this belief. "The Rector's view is that the big technologies of the future will be founded at the interstices of the various faculties," outlines Jon Taylor, former CEO of Imperial College Innovations.
Advertisement

Related Content

The IP Land Grab: New UK Tech Transfer Models
The IP Land Grab: New UK Tech Transfer Models
Photobiotics Ltd.

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090544

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel